Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dropbox Inc DBX

Dropbox, Inc. provides tools to help distributed teams prioritize, get organized, and keep work moving securely from anywhere. Its products include Dropbox Passwords, Vault, Computer Backup, Dropbox Sign, DocSend, Dropbox Capture and FormSwift, among others. Dropbox Passwords allows users to sign into Websites and apps by creating and storing usernames and passwords across devices. Dropbox Vault helps secure and organize sensitive information in the cloud. Computer backup automatically syncs folders on a user's computer to the cloud. Dropbox Sign is an e-signature and document workflow platform that enables customers to easily sign, send and receive documents through its intuitive Web and mobile-based interfaces. DocSend is a secure document sharing and analytics platform. Dropbox Capture is an all-in-one visual communication tool that helps team members share their work and ideas asynchronously. Its customers include individuals, families, teams, and organizations of all sizes.


NDAQ:DBX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by GraceLeeon Jun 03, 2022 5:38am
127 Views
Post# 34728797

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


<< Previous
Bullboard Posts
Next >>